TAGRISSO 80 mg/1

Osimertinib, the active ingredient in TAGRISSO 80 mg/1, is an EGFR tyrosine kinase inhibitor presented as an 80 mg/1 film-coated tablet for oral use. It is used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations in adults. GNH USA supplies TAGRISSO 80 mg/1 as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centers worldwide.

TAGRISSO 80 mg/1 is a targeted therapy designed to inhibit the growth of cancer cells with EGFR mutations, helping to slow tumor progression. This medication is typically prescribed for advanced or metastatic NSCLC, either as a first-line treatment or after other therapies have been tried.

TAGRISSO 80 mg/1 is used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It targets cancer cells with EGFR mutations, helping to slow tumor growth. Here are the key indications:

- EGFR T790M mutation-positive metastatic non-small cell lung cancer: Treatment of patients with this specific mutation who have progressed on or after EGFR tyrosine kinase inhibitor therapy. - First-line treatment of EGFR mutation-positive non-small cell lung cancer: Used as the initial treatment for patients with NSCLC whose tumors have certain EGFR mutations.

TAGRISSO 80 mg/1 can cause various side effects, ranging from common to serious or rare. It is important to be aware of these potential effects when using this medication.

Common Side Effects: - Diarrhea: May come and go during treatment; inform your doctor if it worsens. - Skin and nail problems: Includes pain, itching, dry skin, and rash, often in sun-exposed areas. - Loss of appetite: May occur during treatment. - Reduction in white blood cells: Can increase the risk of infections. - Nosebleeds: A common side effect that may occur during treatment. - Hair thinning: May be experienced by some patients. - Hand-foot syndrome: Includes redness, swelling, and cracking of the skin on palms and soles. - Increase in blood creatinine: May be monitored during treatment.

Serious or Rare Side Effects: - Interstitial lung disease: Sudden difficulty in breathing, cough, or fever; requires immediate medical attention. - Eye problems: Watery eyes, sensitivity to light, eye pain, or vision changes; consult your doctor immediately. - QT prolongation: Changes in heart electrical activity; symptoms include rapid or irregular heartbeats, dizziness, and fainting. - Stevens-Johnson syndrome or toxic epidermal necrolysis: Severe skin reactions; requires immediate medical attention. - Aplastic anemia: A blood disorder where bone marrow stops producing new blood cells; symptoms include persistent fever, bruising, and increased tiredness.

Before using TAGRISSO 80 mg/1, it is important to be aware of certain precautions and warnings. Always follow your doctor's advice and the instructions provided with the medication.

- Inform your doctor if you have a history of lung inflammation or heart problems: May require medical supervision. - Avoid using St. John’s Wort: Concomitant use should be avoided. - Inform your doctor if you are pregnant or breastfeeding: Safety in pregnancy and breastfeeding is not established. - Inform your doctor if you have a history of eye problems: May require monitoring. - Store below 25°C: Keep in the original pack, protect from moisture.

TAGRISSO 80 mg/1 can interact with other medications, which may affect its efficacy or increase the risk of side effects. It is important to be aware of these potential interactions.

Major Interactions (Avoid): - St. John’s Wort: Concomitant use should be avoided as it can decrease the effectiveness of TAGRISSO. - Strong CYP3A inducers: Can decrease the plasma concentrations of osimertinib. - Strong CYP3A inhibitors: Can increase the plasma concentrations of osimertinib, leading to an increased risk of side effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A inducers: May decrease the plasma concentrations of osimertinib; monitor for reduced efficacy. - Moderate CYP3A inhibitors: May increase the plasma concentrations of osimertinib; monitor for increased side effects. - Drugs that prolong the QT interval: May increase the risk of QT prolongation when used concomitantly with TAGRISSO.